Real-World Study: Hybrid Immunity against SARS-CoV-2 Influences the Antibody Levels and Persistency Lasting More than One Year
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Designs and Participant Enrollment
2.2. Laboratory Assessments
2.3. Statistical Analysis
3. Results
3.1. Demographic Characteristics of Study Participants
3.2. An Increased Number of Vaccine Doses Corresponded to a Decrease in the Infection Rate
3.3. The Number of Booster Doses Does Not Increase Total RBD Ig Levels and Their Longevity
3.4. Hybrid Immunity Sustained Prolonged Binding Antibody Levels
3.5. No Association between Occupation and Binding Antibody Levels
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Cucinotta, D.; Vanelli, M. WHO declares COVID-19 a pandemic. Acta. Biomed. 2020, 91, 157–160. [Google Scholar]
- He, J.; Guo, Y.; Mao, R.; Zhang, J. Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis. J. Med. Virol. 2021, 93, 820–830. [Google Scholar] [CrossRef] [PubMed]
- Tan, S.T.; Kwan, A.T.; Rodríguez-Barraquer, I.; Singer, B.J.; Park, H.J.; Lewnard, J.A.; Sears, D.; Lo, N.C. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. Nat. Med. 2023, 29, 358–365. [Google Scholar] [CrossRef] [PubMed]
- Yamamoto, S.; Matsuda, K.; Maeda, K.; Oshiro, Y.; Inamura, N.; Mizoue, T.; Konishi, M.; Takeuchi, J.S.; Horii, K.; Ozeki, M.; et al. Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2. BMC Infect. Dis. 2023, 23, 282. [Google Scholar] [CrossRef]
- Pulliam, J.R.C.; van Schalkwyk, C.; Govender, N.; von Gottberg, A.; Cohen, C.; Groome, M.J.; Dushoff, J.; Mlisana, K.; Moultrie, H. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science 2022, 376, eabn4947. [Google Scholar] [CrossRef] [PubMed]
- Hoffmann, M.; Krüger, N.; Schulz, S.; Cossmann, A.; Rocha, C.; Kempf, A.; Nehlmeier, I.; Graichen, L.; Moldenhauer, A.S.; Winkler, M.S.; et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell 2022, 185, 447–456.e11. [Google Scholar] [CrossRef] [PubMed]
- Regev-Yochay, G.; Gonen, T.; Gilboa, M.; Mandelboim, M.; Indenbaum, V.; Amit, S.; Meltzer, L.; Asraf, K.; Cohen, C.; Fluss, R.; et al. Efficacy of a fourth dose of COVID-19 mRNA vaccine against Omicron. N. Engl. J. Med. 2022, 386, 1377–1380. [Google Scholar] [CrossRef] [PubMed]
- Gilboa, M.; Regev-Yochay, G.; Mandelboim, M.; Indenbaum, V.; Asraf, K.; Fluss, R.; Amit, S.; Mendelson, E.; Doolman, R.; Afek, A.; et al. Durability of immune response after COVID-19 booster vaccination and association with COVID-19 Omicron infection. JAMA Netw. Open. 2022, 5, e2231778. [Google Scholar] [CrossRef]
- Wang, J.; Deng, C.; Liu, M.; Liu, Y.; Li, L.; Huang, Z.; Shang, L.; Jiang, J.; Li, Y.; Mo, R.; et al. A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain. Nat. Commun. 2022, 13, 6866. [Google Scholar] [CrossRef]
- Suntronwong, N.; Yorsaeng, R.; Puenpa, J.; Auphimai, C.; Thongmee, T.; Vichaiwattana, P.; Kanokudom, S.; Duangchinda, T.; Chantima, W.; Pakchotanon, P.; et al. COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against Omicron. Vaccines 2022, 10, 391. [Google Scholar] [CrossRef]
- Arabi, M.; Al-Najjar, Y.; Sharma, O.; Kamal, I.; Javed, A.; Gohil, H.S.; Paul, P.; Al-Khalifa, A.M.; Laws, S.; Zakaria, D. Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: A systematic review. BMC Infect. Dis. 2023, 23, 432. [Google Scholar] [CrossRef] [PubMed]
- Navaratnam, A.M.D.; Shrotri, M.; Nguyen, V.; Braithwaite, I.; Beale, S.; Byrne, T.E.; Fong, W.L.E.; Fragaszy, E.; Geismar, C.; Hoskins, S.; et al. Nucleocapsid and spike antibody responses following virologically confirmed SARS-CoV-2 infection: An observational analysis in the Virus Watch community cohort. Int. J. Infect. Dis. 2022, 123, 104–111. [Google Scholar] [CrossRef] [PubMed]
- Kanokudom, S.; Chansaenroj, J.; Suntronwong, N.; Assawakosri, S.; Yorsaeng, R.; Nilyanimit, P.; Aeemjinda, R.; Khanarat, N.; Vichaiwattana, P.; Klinfueng, S.; et al. The fourth dose of mRNA COVID-19 vaccine following 12 different three-dose regimens: Safety and immunogenicity to Omicron BA.4/BA.5. Vaccines 2023, 11, 570. [Google Scholar] [CrossRef]
- Thailand Department of Disease and Control. Summary of COVID-19 Vaccine Administration in Thailand on 20 September 2022. Available online: https://ddc.moph.go.th/vaccine-covid19/getFiles/7/1670402801471.jpg (accessed on 6 October 2023).
- Thailand Department of Disease and Control. COVID-19 Vaccine in Thailand (Updated 10 March 2023). Available online: https://ddc.moph.go.th/vaccine-covid19/pages/%E0%B8%A3%E0%B8%B2%E0%B8%A2%E0%B8%87%E0%B8%B2%E0%B8%99%E0%B8%84%E0%B8%A7%E0%B8%B2%E0%B8%A1%E0%B8%81%E0%B9%89%E0%B8%B2%E0%B8%A7%E0%B8%AB%E0%B8%99%E0%B9%89%E0%B8%B2%E0%B8%81%E0%B8%B2%E0%B8%A3%E0%B9%83%E0%B8%AB%E0%B9%89%E0%B8%9A%E0%B8%A3%E0%B8%B4%E0%B8%81%E0%B8%B2%E0%B8%A3%E0%B8%89%E0%B8%B5%E0%B8%94%E0%B8%A7%E0%B8%B1%E0%B8%84%E0%B8%8B%E0%B8%B5%E0%B8%99%E0%B9%82%E0%B8%84%E0%B8%A7%E0%B8%B4%E0%B8%94-19 (accessed on 6 October 2023).
- Chansaenroj, J.; Suntronwong, N.; Kanokudom, S.; Assawakosri, S.; Vichaiwattana, P.; Klinfueng, S.; Wongsrisang, L.; Thongmee, T.; Aeemjinda, R.; Khanarat, N.; et al. Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-RBD IgG antibodies, and infection in Thailand: A cross-sectional survey from October 2022 to January 2023. Sci. Rep. 2023, 13, 15595. [Google Scholar] [CrossRef]
- Kanokudom, S.; Chansaenroj, J.; Suntronwong, N.; Assawakosri, S.; Yorsaeng, R.; Nilyanimit, P.; Aeemjinda, R.; Khanarat, N.; Vichaiwattana, P.; Klinfueng, S.; et al. Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens. Int. J. Infect. Dis. 2023, 126, 64–72. [Google Scholar] [CrossRef] [PubMed]
- Suryawanshi, R.; Ott, M. SARS-CoV-2 hybrid immunity: Silver bullet or silver lining? Nat. Rev. Immunol. 2022, 22, 591–592. [Google Scholar] [CrossRef]
- Yorsaeng, R.; Atsawawaranunt, K.; Suntronwong, N.; Kanokudom, S.; Chansaenroj, J.; Assawakosri, S.; Nilyanimit, P.; Aeemjinda, R.; Khanarat, N.; Wongsrisang, L.; et al. SARS-CoV-2 antibody dynamics after COVID-19 vaccination and infection: A real-world cross-sectional analysis. Vaccines 2023, 11, 1184. [Google Scholar] [CrossRef] [PubMed]
- Edelstein, M.; Wiegler Beiruti, K.; Ben-Amram, H.; Beer, N.; Sussan, C.; Batya, P.; Zarka, S.; Abu Jabal, K. Vaccine-induced and hybrid immunity to SARS-CoV-2 after three or four doses of BNT162b2-results from 22 months follow-up of a healthcare workers cohort, Israel, 2020–2022. Int. J. Infect. Dis. 2023, 135, 57–62. [Google Scholar] [CrossRef]
- Pallett, S.J.C.; Heskin, J.; Keating, F.; Mazzella, A.; Taylor, H.; Patel, A.; Lamb, G.; Sturdy, D.; Eisler, N.; Denny, S.; et al. Hybrid immunity in older adults is associated with reduced SARS-CoV-2 infections following BNT162b2 COVID-19 immunisation. Commun. Med. 2023, 3, 83. [Google Scholar] [CrossRef]
- de La Vega, M.A.; Polychronopoulou, E.; Xiii, A.; Ding, Z.; Chen, T.; Liu, Q.; Lan, J.; Nepveu-Traversy, M.E.; Fausther-Bovendo, H.; Zaidan, M.F.; et al. SARS-CoV-2 infection-induced immunity reduces rates of reinfection and hospitalization caused by the Delta or Omicron variants. Emerg. Microbes Infect. 2023, 12, e2169198. [Google Scholar] [CrossRef]
- Szekely, J.; Swangphon, P.; Nanakorn, N.; Chaimuti, P.; Nualnoi, T.; Wongwitwichot, P.; Somapa, N.; Somapa, D.; Pengsakul, T. Breakthrough SARS-CoV-2 Omicron variant in individuals primed with heterologous vaccines enhances inhibition performance of neutralizing antibody to BA.2 parental lineage. Vaccines 2023, 11, 1230. [Google Scholar] [CrossRef] [PubMed]
- Muik, A.; Lui, B.G.; Bacher, M.; Wallisch, A.K.; Toker, A.; Finlayson, A.; Krüger, K.; Ozhelvaci, O.; Grikscheit, K.; Hoehl, S.; et al. Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5. Sci. Immunol. 2022, 7, eade2283. [Google Scholar] [CrossRef] [PubMed]
- Du, Z.; Wang, Y.; Bai, Y.; Wang, L.; Cowling, B.J.; Meyers, L.A. Estimate of COVID-19 deaths, China, December 2022-February 2023. Emerg. Infect. Dis. 2023, 29, 2121–2124. [Google Scholar] [CrossRef] [PubMed]
- WHO’s Strategic Advisory Group on Immunization (SAGE). COVID-19 Advice for the Public: Getting Vaccinated (Updated on 4 August 2023). Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice (accessed on 6 October 2023).
- Department of Health and Social Care (United Kingdom). JCVI Statement on the COVID-19 Vaccination Programme for 2023: 8 November 2022. Available online: https://www.gov.uk/government/publications/covid-19-vaccination-programme-for-2023-jcvi-interim-advice-8-november-2022/jcvi-statement-on-the-covid-19-vaccination-programme-for-2023-8-november-2022#fn:1 (accessed on 6 October 2023).
- Department of Health and Care (Australia). Is It True? Do People Need All the Recommended Doses of the COVID-19 Vaccine? (Updated 8 May 2023). Available online: https://www.health.gov.au/our-work/covid-19-vaccines/is-it-true/is-it-true-do-people-need-all-the-recommended-doses-of-the-covid-19-vaccine#:~:text=Booster%20doses%20are%20not%20recommended,factors%20for%20severe%20COVID%2D19 (accessed on 6 October 2023).
- Ayoubkhani, D.; Bosworth, M.L.; King, S.; Pouwels, K.B.; Glickman, M.; Nafilyan, V.; Zaccardi, F.; Khunti, K.; Alwan, N.A.; Walker, A.S. Risk of long COVID in people infected with Severe Acute Respiratory Syndrome Coronavirus 2 after 2 doses of a coronavirus disease 2019 vaccine: Community-based, matched cohort study. Open Forum Infect. Dis. 2022, 9, ofac464. [Google Scholar] [CrossRef]
- Al-Aly, Z.; Bowe, B.; Xie, Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat. Med. 2022, 28, 1461–1467. [Google Scholar] [CrossRef]
- Notarte, K.I.; Catahay, J.A.; Velasco, J.V.; Pastrana, A.; Ver, A.T.; Pangilinan, F.C.; Peligro, P.J.; Casimiro, M.; Guerrero, J.J.; Gellaco, M.M.L.; et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine 2022, 53, 101624. [Google Scholar] [CrossRef]
- World Health Organization (WHO). Statement on the Fifteenth Meeting of the IHR (2005) Emergency Committee on the COVID-19 Pandemic (Announced on May 2023). Available online: https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic (accessed on 6 October 2023).
Characteristics | All Participants | (1) <6 | (2) 6 to <9 | (3) 9 to <12 | (4) ≥12 |
---|---|---|---|---|---|
Total n (%) | 771 | 88 (11.4) | 180 (23.3) | 292 (37.9) | 211 (27.4) |
Female n (%) | 608 (78.9) | 70 (79.5) | 144 (80.4) | 235 (80.5) | 159 (75.0) |
Age years, | |||||
Med | 42.0 | 36.5 | 43.0 | 42.0 | 41.0 |
[IQR] | [30.0–52.0] | [27.0–48.8] | [33.0–56.0] | [30.0–51.0] | [30.0–52.0] |
Occupation n (%) | |||||
| 267 (34.6) | 45 (51.1) | 53 (29.6) | 94 (32.2) | 75 (35.4) |
| 504 (65.4) | 43 (48.9) | 126 (70.4) | 198 (67.8) | 137 (64.6) |
Duration since last vaccination and/or vaccination plus infection, days | |||||
Med | 299.0 | 141.0 | 231.5 | 308.5 | 440.0 |
[IQR] | [242.0–378.0] | [126.3–159.5] | [207.0–250.0] | [290.0–331.0] | [397.0–481.5] |
Serostatus Classified by Total anti-N Ig | Infection History # | |||
Yes | No | Total | ||
Npos ¶ | 445 (57.7%) | 108 (14.0%) * | 553 (71.7%) | |
Nneg ¶ | 6 (0.8%) ** | 212 (27.5%) | 218 (28.3%) | |
Total | 451 (58.5%) | 320 (41.5%) | 771 (100.0%) |
The Number of Vaccine Doses | The Npos Rate |
---|---|
≥5 doses | 69.0% (167 out of 242) |
4 doses | 70.5% (152 out of 219) |
3 doses | 75.4% (101 out of 134) |
2 doses | 93.1% (27 out of 29) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kanokudom, S.; Chansaenroj, J.; Assawakosri, S.; Suntronwong, N.; Yorsaeng, R.; Wongsrisang, L.; Aeemjinda, R.; Vichaiwattana, P.; Klinfueng, S.; Thatsanathorn, T.; et al. Real-World Study: Hybrid Immunity against SARS-CoV-2 Influences the Antibody Levels and Persistency Lasting More than One Year. Vaccines 2023, 11, 1693. https://doi.org/10.3390/vaccines11111693
Kanokudom S, Chansaenroj J, Assawakosri S, Suntronwong N, Yorsaeng R, Wongsrisang L, Aeemjinda R, Vichaiwattana P, Klinfueng S, Thatsanathorn T, et al. Real-World Study: Hybrid Immunity against SARS-CoV-2 Influences the Antibody Levels and Persistency Lasting More than One Year. Vaccines. 2023; 11(11):1693. https://doi.org/10.3390/vaccines11111693
Chicago/Turabian StyleKanokudom, Sitthichai, Jira Chansaenroj, Suvichada Assawakosri, Nungruthai Suntronwong, Ritthideach Yorsaeng, Lakkhana Wongsrisang, Ratchadawan Aeemjinda, Preeyaporn Vichaiwattana, Sirapa Klinfueng, Thaksaporn Thatsanathorn, and et al. 2023. "Real-World Study: Hybrid Immunity against SARS-CoV-2 Influences the Antibody Levels and Persistency Lasting More than One Year" Vaccines 11, no. 11: 1693. https://doi.org/10.3390/vaccines11111693